Mga Industriya

• Reset all ×
• Mga Agham sa Buhay ×

Showing 491–500 ng mga 506 results

Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low

• 

  Autoimmune Diseases Treatment Market in China 2021

  The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 27% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Chimeric Antigen Receptor (CAR) T-Cell Therapy Market in China 2021

  In terms of revenue, the chimeric antigen receptor (CAR) T-cell therapy market in China is projected to grow at a compound annual growth rate (CAGR) ng mga 17% sa panahon ng pagsusuri ng 2021 sa 2027, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the chimeric antigen receptor (CAR) T-cell therapy market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Myelodysplastic Syndromes (MDS) Drug Market in China 2021

  The myelodysplastic syndromes (MDS) drug market in China in terms of revenue is set to grow by US$ 548 million during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 17.3% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the myelodysplastic syndromes (MDS) drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Non-Small Cell Lung Cancer (NSCLC) Drug Market in China 2021

  The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 17.1% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Hepatocellular Carcinoma (HCC) Drug Market in China 2021

  The hepatocellular carcinoma (HCC) drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 21.7% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the hepatocellular carcinoma (HCC) drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Diffuse Large B Cell Lymphomas (DLBCL) Drug Market in China 2021

  The diffuse large B cell lymphomas (DLBCL) drug market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 22.2% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the diffuse large B cell lymphomas (DLBCL) drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Multiple Myeloma Drug Market in China 2021

  The multiple myeloma drug market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 18.8% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the multiple myeloma drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Oncology Drug Market in China 2021

  The oncology drug market in China in terms of revenue is set to grow by US$ 42 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 13.8% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the oncology drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  Moderate and Severe Dry Eye Disease Market in China 2021

  The moderate and severe dry eye disease market in China in terms of revenue is set to grow by US$ 570 million during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 30.4% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the moderate and severe dry eye disease market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450
• 

  NMOSD (Neuromyelitis Optica Spectrum Disorder) Drug Market in China 2021

  In terms of revenue, the NMOSD (neuromyelitis optica spectrum disorder) drug market in China is projected to grow at a compound annual growth rate (CAGR) ng mga 26.8% sa panahon ng pagsusuri ng 2021 sa 2027, ayon sa data at analytics company na StrategyHelix. Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the NMOSD (neuromyelitis optica spectrum disorder) drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

  USD 450